Press release content from Business Wire. The AP news staff was not involved in its creation.
Fuzionaire Radioisotope Technologies K.K. and Nihon Medi-Physics Enter Feasibility Study Agreement
January 26, 2021 GMT
TOKYO (BUSINESS WIRE) Jan 26, 2021
Fuzionaire Radioisotope Technologies K.K. (“FRIT”) today announced that it has entered into a feasibility study agreement with Nihon Medi-Physics Co., Ltd. (“NMP”), a leading radiopharmaceutical company in Japan, engaged in R&D, manufacturing, and distribution.
Founded in 2019, FRIT is a joint venture between radiopharmaceutical companies Fuzionaire Diagnostics, Inc. (“Fuzionaire Dx”) and Japan Medical Isotope Technology Development K.K. to develop and commercialize Fuzionaire Dx’s radiopharmaceutical technologies in Japan. Founded in 1973, NMP is a joint venture between Sumitomo Chemical Company, Limited and GE Healthcare.